

## 4DMedical converts Integral Diagnostics pilot into commercial contract

---

15 April 2025

### Highlights

- 4DMedical signs commercial contract with Integral Diagnostics, the second largest diagnostic imaging provider in Australia
  - Contract follows a successful pilot with Lake Imaging, and will provide general practitioners, respiratory specialists and cardiologists with greater access to 4DMedical's technology
- 

**Melbourne, Australia, 15 April 2025:** 4DMedical Limited (ASX: 4DX, "4DMedical", or the "Company"), a global leader in respiratory imaging technology, today announces the conversion of its pilot program into a commercial contract with Lake Imaging, a part of Integral Diagnostics (ASX:IDX).

### Integral Diagnostics is a leading provider of medical imaging

For over 20 years, Lake Imaging has serviced the Central and Western Victoria area with radiology services, and was one of the original practices that merged to form Integral Diagnostics. Integral Diagnostics is a leading provider of medical imaging services across Australia and New Zealand, and following the merger with Capitol Health in December 2024, is now the second largest diagnostic imaging provider in Australia. Integral Diagnostics employs some of Australasia's leading radiologists and diagnostic imaging specialists in a unique medical leadership model that ensures quality patient care, service and access.

### 4DMedical successfully converts Integral Diagnostics pilot into commercial contract

4DMedical is pleased to announce the successful transition of the pilot program, announced in October 2023, to a full commercial contract. This expansion will see 4DMedical's breakthrough lung imaging technology available for routine clinical use at Lake Imaging locations including Ballarat, Albury, North Melbourne, Geelong, Warrnambool, and other locations as agreed between the parties from time to time.

General practitioners, respiratory specialists, cardiologists, and their patients will now have greater access to the rich lung-function data provided by CT LVAS™ across Victoria. These increased services enable healthcare providers to offer enhanced diagnostic capabilities for respiratory illnesses to their patients, ensuring timely and accurate diagnoses that improve patient outcomes.

### 4DMedical MD/CEO and Founder Andreas Fouras said:

*This contract is a direct result of the strong interest from doctors to use our products in clinical practice and continues 4DMedical's record of converting 100% of pilot programs into full commercial contracts. This is another important step in 4DMedical's mission to revolutionise lung health and further strengthens our commercial presence in Australia.*

–ENDS–

Authorised by the 4DMedical Board of Directors.



## Contacts

### Corporate

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

### Administration

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

## About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)